| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Total revenue | 73,468 | 70,008 | 62,465 | 67,771 |
| Cost of revenue | 8,177 | 7,115 | 8,574 | 6,035 |
| Selling, general and administrative | 26,182 | 26,018 | 20,339 | 42,367 |
| Research and development | 8,435 | 7,432 | 5,743 | 3,047 |
| Restructuring | 0 | 114 | 1,533 | - |
| Other expense, net | -929 | -9,246 | -4,429 | -4,574 |
| Total operating expenses | 43,723 | 49,925 | 40,618 | 56,023 |
| Income (loss) from operations | 29,745 | 20,083 | 21,847 | 11,748 |
| Interest income | 3,316 | 3,190 | 3,569 | 4,267 |
| Interest expense | 1,099 | 1,117 | 1,067 | 1,208 |
| Net income before income taxes | 31,962 | 22,156 | 24,349 | 14,807 |
| Income tax expense | 411 | 643 | 1,005 | 457 |
| Net income | 31,551 | 21,513 | 23,344 | 14,350 |
| Unrealized gain (loss) on available-for-sale securities | 156 | -80 | -178 | 474 |
| Comprehensive income | 31,707 | 21,433 | 23,166 | 14,824 |
| Basic (in shares) | 131,808,000 | 134,873,000 | 138,917,000 | 143,051,000 |
| Basic (in usd per share) | 0.24 | 0.16 | 0.17 | 0.1 |
| Diluted (in shares) | 136,008,000 | 137,526,000 | 143,199,000 | 145,651,000 |
| Diluted (in usd per share) | 0.23 | 0.16 | 0.16 | 0.1 |
Aurinia Pharmaceuticals Inc. (AUPH)
Aurinia Pharmaceuticals Inc. (AUPH)